Lineage Cell Therapeutics (LCTX) announced that it has entered into a research collaboration with and through an investment from William Demant Invest. WDI is an evergreen investor and the holding company for William Demant Foundation’s investment activities – a majority shareholder of Demant. The parties will jointly advance Lineage’s auditory neuronal cell transplant, ReSonance, for the treatment of hearing loss. The multi-year research collaboration covers preclinical development activities, including cell manufacturing, proof-of-concept studies, translational/functional models, delivery development, outcome measures, regulatory strategy, and market analysis, to support a potential IND/CTA filing. WDI will fund up to $12M in research collaboration costs over the period, with development activities jointly conducted and managed by Lineage and scientists from Eriksholm Research Centre, part of Oticon, which is a subsidiary of the Demant Group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX:
- Promising Developments and Strong Financial Position Support Buy Rating for Lineage Cell Therapeutics
- Lineage Cell Therapeutics: Strong Financials and Promising Clinical Data Drive Buy Rating
- Lineage Cell Therapeutics Reports Q2 2025 Progress and Challenges
- Lineage Cell Therapeutics reports Q2 EPS (13c), consensus (3c)
- Lineage Cell Therapeutics: Buy Rating Affirmed Amid OPC1 Program Milestone and Strategic Financial Positioning